Evidence map›Paper›PMID 33319463›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Piptides: New, Easily Accessible Chemotypes For Interactions With Biomolecules.

Maritess Arancillo, Jaru Taechalertpaisarn, Xiaowen Liang, Kevin Burgess

Open access · greenAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maritess ArancilloDepartment of Chemistry, Texas A & M University, Box 30012, College Station, TX, 77842, USA.ORCID 0000-0001-6281-346X
Jaru TaechalertpaisarnDepartment of Chemistry, Texas A & M University, Box 30012, College Station, TX, 77842, USA.ORCID 0000-0002-6369-0171
Xiaowen LiangCenter for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, 77030, USA.ORCID 0000-0002-6174-2951
Kevin BurgessDepartment of Chemistry, Texas A & M University, Box 30012, College Station, TX, 77842, USA.ORCID 0000-0001-6597-1842
Texas A&M University · USTexas A&M Health Science Center · US

Funding

Evaluation Of Trk Probes In Models For Dry Eye DiseaseR01EY029695 · NEI · TEXAS A&M UNIVERSITY · PI BURGESS, KEVIN · 2019 to 2021
$1.7M
NEI NIH HHS R01 EY029695
6 · The paper itself

Abstract

Small molecule probe development is pivotal in biomolecular science. Research described here was undertaken to develop a non-peptidic chemotype, piptides, that is amenable to convenient, iterative solid-phase syntheses, and useful in biomolecular probe discovery. Piptides can be made from readily accessible pip acid building blocks and have good proteolytic and pH stabilities. An illustrative application of piptides against a protein-protein interaction (PPI) target was explored. The Exploring Key Orientations (EKO) strategy was used to evaluate piptide candidates for this. A library of only 14 piptides contained five members that disrupted epidermal growth factor (EGF) and its receptor, EGFR, at low micromolar concentrations. These piptides also caused apoptotic cell death, and antagonized EGF-induced phosphorylation of intracellular tyrosine residues in EGFR.

Indexed as

Epidermal Growth FactorErbB ReceptorsHumansHydrogen-Ion ConcentrationMolecular StructurePeptidesPhosphorylationProtein BindingEpidermal Growth FactorErbB ReceptorsPeptidescancerEGFpeptidomimeticsprotein-protein interactionssolid-phase synthesis

Identifiers

PMID33319463
PMCPMC7940574
OpenAlexW3111425429

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.